期刊
CLINICA CHIMICA ACTA
卷 412, 期 23-24, 页码 2022-2030出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.cca.2011.07.023
关键词
Urinary biomarker; Chemokine; Glomerulonephritis; Acute kidney injury; Polycystic kidney disease; Diabetic nephropathy
资金
- Roche Palo Alto
- AstraZeneca Limited
- Cyclacel Limited
- Baxter Biosciences
- Swiss National Science Foundation
- Novartis Foundation
- Medical Research Council
- Wellcome Trust
- Imperial College Healthcare Charity
- National Institute for Health Research (NIHR) Biomedical Research Centre
Monocyte chemoattractant protein-1 (MCP-1/CCL2) has a critical role in the development of various renal diseases. Data from disease specific experimental animal models and clinical studies confirm that MCP-1 plays an important part in the pathogenesis of renal diseases. The action of MCP-1 in these studies has been shown to be more complex than the traditional concept of monocyte/macrophage recruitment to the inflammatory site. MCP-1 is expressed in renal tissues and it is detectable in urine of patients with a variety of renal diseases. Measurement of urinary levels of MCP-1 can provide valuable information not only for the diagnosis of active renal disease, but also for monitoring of response to therapy. Urinary MCP-1 measurement can provide help with evaluation of the prognosis in various renal diseases. Furthermore, selective targeting of MCP-1 could be an effective treatment in suppressing a number of renal diseases as blocking MCP-1 has already been shown to ameliorate renal diseases in experimental animal models. The advantage of measuring urinary MCP-1 rather than the conventional markers must now be validated using a larger cohort of patients in different renal diseases. Also the therapeutic potential of MCP-1 targeting agents needs to be investigated in clinical studies. Crown Copyright (C) 2011 Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据